. Author manuscript; available in PMC: 2016 Jan 28.

Published in final edited form as: J Nucl Med. 2015 Oct 22;57(1):46–53. doi: 10.2967/jnumed.115.163782

Table 4. Sensitivity, with Equivocal Lesions Considered Either Positive or Negative for Metastases in 2 Separate Analyses, for ¹⁸F-DCFBC PET and CIM as Estimated by GEE Regression Model Analysis.

Modality	Sensitivity (equivocal lesions considered negative)	Sensitivity (equivocal lesions considered positive)
¹⁸F-DCFBC PET	0.92 (0.80–0.97)	0.88 (0.70–0.96)

CECT	0.64 (0.41–0.82)	0.77 (0.58–0.89)

BS	0.40 (0.20–0.65)	0.43 (0.25–0.63)

CIM (BS and CECT)	0.71 (0.49–0.86)	0.82 (0.60–0.93)

Data in parentheses are 95% CIs.

Table 4. Sensitivity, with Equivocal Lesions Considered Either Positive or Negative for Metastases in 2 Separate Analyses, for 18F-DCFBC PET and CIM as Estimated by GEE Regression Model Analysis.